The content on this site is intended for healthcare professionals only
Dr Jayant Vaidya speaks to ecancer about long term survival and local control outcomes of TARGIT-A a randomised clinical trial which studied single dose targeted intraoperative radiotherapy (IORT) during lumpectomy for early breast cancer.
The further analysis of TARGIT-A showed a sub-group analysis among individual breast cancer subtypes. Researchers have also developed an online tool with a risk adapted approach to help people determine which treatment course may be best for each individual breast cancer patient. It was also found that IORT helps to protect against deaths from other causes such as heart attacks for breast cancer patients.
Dr Jayant Vaidya concludes by highlighting how these results will impact the future treatment of breast cancer.
Read the full study here.
Visit the TARGIT website here.
ESMO 2024: Best practice in HRRm testing in patients with metastatic prostate cancer
First-line NALIRIFOX shows improvement in OS and PFS in metastatic pancreatic cancer
Breast and emerging indications for IORT
The advantages of IORT for early breast cancer treatment
The pros and cons of breast IORT and ultra hypofractionation (FR)
SOFT study: Clinical relevance of genomic alterations in premenopausal HR+, HER2- early breast cancer
Global adoption of single-shot targeted IORT for breast cancer
IORT at the Asian Hospital and Medical Center
Insights from TARGIT-A trial of targeted IORT during lumpectomy for breast cancer
